Advertisement

International Urology and Nephrology

, Volume 48, Issue 6, pp 851–857 | Cite as

The relation of postprandial plasma glucose and serum endostatin to the urinary albumin excretion of residents with prediabetes: results from the Kyushu and Okinawa Population Study (KOPS)

  • Motohiro ShimizuEmail author
  • Norihiro Furusyo
  • Yuuki Tanaka
  • Yoshifumi Kato
  • Fujiko Mitsumoto-Kaseida
  • Koji Takayama
  • Kazuya Ura
  • Satoshi Hiramine
  • Takeo Hayashi
  • Hiroaki Ikezaki
  • Takeshi Ihara
  • Haru Mukae
  • Eiichi Ogawa
  • Kazuhiro Toyoda
  • Mosaburo Kainuma
  • Masayuki Murata
  • Jun Hayashi
Nephrology - Original Paper

Abstract

Background

Previous clinical studies have shown that the circulating level of endostatin is related to kidney injury. We hypothesized that the impact of HbA1c, fasting, and postprandial plasma glucose on urinary albumin excretion would be related to the serum endostatin level.

Methods

A cross-sectional, community-based population study of 1057 Japanese residents was conducted. Of these subjects, 162 with a fasting plasma glucose value between 5.5 and 6.9 mmol/L and an HbA1c level of <6.5 % received an oral glucose tolerance test, had serum endostatin measured, and had the urinary albumin/creatinine ratio (UACR) calculated.

Results

In multivariate analysis, 2-h postprandial plasma glucose (β = 0.26, P < 0.01) was significantly associated with log-transformed UACR, independently of fasting plasma glucose (β = 0.14, P = 0.28) and HbA1c (β = −0.08, P = 0.57). When divided by the median value of endostatin (82.2 ng/mL), 2-h postprandial plasma glucose (β = 0.38, P = 0.01) remained significantly associated with the log-transformed UACR of the participants below the median, while the fasting plasma glucose (β = 0.34, P = 0.046) was independently associated with the log-transformed UACR of participants above the median.

Conclusion

Postprandial plasma glucose was independently associated with the urinary albumin excretion of the residents with prediabetes. Moreover, this relationship was limited to residents with a serum endostatin level below the median.

Keywords

Diabetic nephropathy Postprandial plasma glucose Serum endostatin Urinary albumin excretion Prediabetes 

Notes

Acknowledgments

We are grateful to Drs. Kyoko Okada, Sakiko Hayasaki, Ayaka Komori, Rinne Takeda, Sho Yamasaki, Azusa Hatashima, and Masaru Sakiyama from our department for their assistance.

Funding

This study was funded by the Japan Multi-institutional Collaborative Cohort Study (J-MICC Study), a Scientific Support Programs for Cancer Research Grant-in-Aid for Scientific Research on Innovative Areas (Grant Number 221S0001), and a Grant-in-Aid for Comprehensive Research (Priority Areas of Cancer: Grant Number 17015018) of the 21st Century COE Program from the Ministry of Education, Culture, Sports Science, and Technology of Japan. This research was partially supported by Ministry of Education, Science, Sports and Culture, Grant-in-Aid for Scientific Research (C), 2014-2016 (26461506, Norihiro Furusyo).

Compliance with ethical standards

Conflict of interest

Norihiro Furusyo has received grants from Taisho Toyama Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., and Bristol-Myers Squibb. The other authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Ritz E, Orth SR (1999) Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341:1127–1133CrossRefPubMedGoogle Scholar
  2. 2.
    de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J (2011) Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305:2532–2539CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRefPubMedGoogle Scholar
  4. 4.
    Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O’Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I (2010) Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376:419–430CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bakris GL, Molitch M (2014) Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care 37(3):867–875. doi: 10.2337/dc13-1870 CrossRefPubMedGoogle Scholar
  6. 6.
    Shiraiwa T, Kaneto H, Miyatsuka T, Kato K, Yamamoto K, Kawashima A, Kanda T, Suzuki M, Imano E, Matsuhisa M, Hori M, Yamasaki Y (2005) Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients. Biochem Biophys Res Commun 336:339–345CrossRefPubMedGoogle Scholar
  7. 7.
    Metcalf PA, Baker JR, Scragg RK, Dryson E, Scott AJ, Wild CJ (1993) Microalbuminuria in a middle-aged workforce. Effect of hyperglycemia and ethnicity. Diabetes Care 16:1485–1493CrossRefPubMedGoogle Scholar
  8. 8.
    Muris DM, Houben AJ, Schram MT, Stehouwer CD (2012) Microvascular dysfunction is associated with a higher incidence of type 2 diabetes mellitus: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 32:3082–3094CrossRefPubMedGoogle Scholar
  9. 9.
    Beck-Nielsen H, Groop LC (1994) Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 94:1714–1721CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Monnier L, Colette C, Dunseath GJ, Owens DR (2007) The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 30:263–269CrossRefPubMedGoogle Scholar
  11. 11.
    Seppinen L, Pihlajaniemi T (2011) The multiple functions of collagen XVIII in development and disease. Matrix Biol 30:83–92CrossRefPubMedGoogle Scholar
  12. 12.
    Arnlov J, Ruge T, Ingelsson E, Larsson A, Sundstrom J, Lind L (2013) Serum endostatin and risk of mortality in the elderly: findings from 2 community-based cohorts. Arterioscler Thromb Vasc Biol 33:2689–2695CrossRefPubMedGoogle Scholar
  13. 13.
    Ruge T, Carlsson AC, Larsson TE, Carrero JJ, Larsson A, Lind L, Arnlov J (2014) Endostatin level is associated with kidney injury in the elderly: findings from two community-based cohorts. Am J Nephrol 40:417–424CrossRefPubMedGoogle Scholar
  14. 14.
    Chen J, Hamm LL, Kleinpeter MA, Husserl F, Khan IE, Chen CS, Liu Y, Mills KT, He C, Rifai N, Simon EE, He J (2012) Elevated plasma levels of endostatin are associated with chronic kidney disease. Am J Nephrol 35:335–340CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Carlsson AC, Ruge T, Sundstrom J, Ingelsson E, Larsson A, Lind L, Arnlov J (2013) Association between circulating endostatin, hypertension duration, and hypertensive target-organ damage. Hypertension 62:1146–1151CrossRefPubMedGoogle Scholar
  16. 16.
    Watorek E, Paprocka M, Dus D, Kopec W, Klinger M (2011) Endostatin and vascular endothelial growth factor: potential regulators of endothelial progenitor cell number in chronic kidney disease. Pol Arch Med Wewn 121:296–301PubMedGoogle Scholar
  17. 17.
    Charytan DM, Padera R, Helfand AM, Zeisberg M, Xu X, Liu X, Himmelfarb J, Cinelli A, Kalluri R, Zeisberg EM (2014) Increased concentration of circulating angiogenesis and nitric oxide inhibitors induces endothelial to mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease. Int J Cardiol 176:99–109CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Shimizu M, Furusyo N, Mitsumoto F, Takayama K, Ura K, Hiramine S, Ikezaki H, Ihara T, Mukae H, Ogawa E, Toyoda K, Kainuma M, Murata M, Hayashi J (2015) Subclinical carotid atherosclerosis and triglycerides predict the incidence of chronic kidney disease in the Japanese general population: results from the Kyushu and Okinawa Population Study (KOPS). Atherosclerosis 238:207–212CrossRefPubMedGoogle Scholar
  19. 19.
    Ikezaki H, Furusyo N, Okada K, Ihara T, Hayashi T, Ogawa E, Kainuma M, Murata M, Hayashi J (2014) The utility of urinary myo-inositol as a marker of glucose intolerance. Diabetes Res Clin Pract 103:88–96CrossRefPubMedGoogle Scholar
  20. 20.
    Ohnishi H, Sawayama Y, Furusyo N, Maeda S, Tokunaga S, Hayashi J (2010) Risk factors for and the prevalence of peripheral arterial disease and its relationship to carotid atherosclerosis: the Kyushu and Okinawa Population Study (KOPS). J Atheroscler Thromb 17:751–758CrossRefPubMedGoogle Scholar
  21. 21.
    Furusyo N, Koga T, Ai M, Otokozawa S, Kohzuma T, Ikezaki H, Schaefer EJ, Hayashi J (2011) Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese Population Study: results from the Kyushu and Okinawa Population Study (KOPS). Diabetologia 54:3028–3036CrossRefPubMedGoogle Scholar
  22. 22.
    Unno M, Furusyo N, Mukae H, Koga T, Eiraku K, Hayashi J (2012) The utility of visceral fat level by bioelectrical impedance analysis in the screening of metabolic syndrome - the results of the Kyushu and Okinawa Population Study (KOPS). J Atheroscler Thromb 19:462–470CrossRefPubMedGoogle Scholar
  23. 23.
    Furusyo N, Koga T, Ai M, Otokozawa S, Kohzuma T, Ikezaki H, Schaefer EJ, Hayashi J (2013) Plasma glycated albumin level and atherosclerosis: results from the Kyushu and Okinawa Population Study (KOPS). Int J Cardiol 167:2066–2072CrossRefPubMedGoogle Scholar
  24. 24.
    Ihara T, Furusyo N, Hayashi T, Toyoda K, Murata M, Hayashi J (2013) A population-based epidemiological survey of human parvovirus B19 infection: a project of the Kyushu and Okinawa Population Study (KOPS). Arch Virol 158:2465–2472CrossRefPubMedGoogle Scholar
  25. 25.
    Furusyo N, Ai M, Okazaki M, Ikezaki H, Ihara T, Hayashi T, Hiramine S, Ura K, Kohzuma T, Schaefer EJ, Hayashi J (2013) Serum cholesterol and triglyceride reference ranges of twenty lipoprotein subclasses for healthy Japanese men and women. Atherosclerosis 231:238–245CrossRefPubMedGoogle Scholar
  26. 26.
    Ikezaki H, Furusyo N, Ihara T, Hayashi T, Ura K, Hiramine S, Mitsumoto F, Takayama K, Murata M, Kohzuma T, Ai M, Schaefer EJ, Hayashi J (2015) Glycated albumin as a diagnostic tool for diabetes in a general Japanese population. Metabolism 64:698–705CrossRefPubMedGoogle Scholar
  27. 27.
    Coleman A, Steel S, Freeman P, de Greeff A, Shennan A (2008) Validation of the Omron M7 (HEM-780-E) oscillometric blood pressure monitoring device according to the British Hypertension Society protocol. Blood Press Monit 13:49–54CrossRefPubMedGoogle Scholar
  28. 28.
    American Diabetes Association (2012) Diagnosis and classification of diabetes mellitus. Diabetes Care 35(Suppl 1):S64–71CrossRefGoogle Scholar
  29. 29.
    Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992CrossRefPubMedGoogle Scholar
  30. 30.
    Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681–1687CrossRefPubMedGoogle Scholar
  31. 31.
    Xu YZ, Zhang X, Wang L, Zhang F, Qiu Q, Liu ML, Zhang GR, Wu XL (2013) An increased circulating angiotensin II concentration is associated with hypoadiponectinemia and postprandial hyperglycemia in men with nonalcoholic fatty liver disease. Intern Med 52:855–861CrossRefPubMedGoogle Scholar
  32. 32.
    Li SY, Huang PH, Yang AH, Tarng DC, Yang WC, Lin CC, Chen JW, Schmid-Schonbein G, Lin SJ (2014) Matrix metalloproteinase-9 deficiency attenuates diabetic nephropathy by modulation of podocyte functions and dedifferentiation. Kidney Int 86:358–369CrossRefPubMedGoogle Scholar
  33. 33.
    Peeters SA, Engelen L, Buijs J, Chaturvedi N, Fuller JH, Schalkwijk CG, Stehouwer CD (2015) Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study. Cardiovasc Diabetol 14:31CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Tanaka S, Takase H, Dohi Y, Kimura G (2013) The prevalence and characteristics of microalbuminuria in the general population: a cross-sectional study. BMC Res Notes 6:256CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Won JC, Lee YJ, Kim JM, Han SY, Noh JH, Ko KS, Rhee BD, Kim DJ (2013) Prevalence of and factors associated with albuminuria in the Korean adult population: the 2011 Korea National Health and Nutrition Examination Survey. PLoS ONE 8:e83273CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Murussi M, Campagnolo N, Beck MO, Gross JL, Silveiro SP (2007) High-normal levels of albuminuria predict the development of micro- and macroalbuminuria and increased mortality in Brazilian Type 2 diabetic patients: an 8-year follow-up study. Diabet Med 24:1136–1142CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2016

Authors and Affiliations

  • Motohiro Shimizu
    • 1
    Email author
  • Norihiro Furusyo
    • 1
  • Yuuki Tanaka
    • 1
  • Yoshifumi Kato
    • 1
  • Fujiko Mitsumoto-Kaseida
    • 1
  • Koji Takayama
    • 1
  • Kazuya Ura
    • 1
  • Satoshi Hiramine
    • 1
  • Takeo Hayashi
    • 1
  • Hiroaki Ikezaki
    • 1
  • Takeshi Ihara
    • 1
  • Haru Mukae
    • 1
  • Eiichi Ogawa
    • 1
  • Kazuhiro Toyoda
    • 1
  • Mosaburo Kainuma
    • 1
  • Masayuki Murata
    • 1
  • Jun Hayashi
    • 1
    • 2
  1. 1.Department of General Internal MedicineKyushu University HospitalFukuokaJapan
  2. 2.Kyushu General Internal Medicine CenterHaradoi HospitalFukuokaJapan

Personalised recommendations